At AusBiotech, we are proud to highlight Australian life sciences innovators through our Spotlight series — shining a light on local homegrown life sciences capabilities that reflect Australia's broader vision for health innovation, commercialisation, and sovereign manufacturing.
Our next Spotlight features BiomeBank — an Adelaide-based biotech on a mission to restore gut microbial ecology. In 2023, BiomeBank made history with the world's first approved microbial therapy, now available across Australia to treat Clostridioides difficile infection — a serious and potentially life-threatening condition.
With a proprietary platform that co-cultures complex microbial communities and the world's largest gut microbiome culture collection, BiomeBank is charting new territory. The company is building a pipeline of live biotherapeutic products designed to replicate the complexity and function of a healthy gut microbiome — a capability unmatched globally.
Stories like these reflect the critical importance of translation, development, and commercialisation pathways for Australia's life sciences breakthroughs. They underscore why AusBiotech continues to advocate for policy reform, investment attraction, and ecosystem development through initiatives such as the National Life Sciences Strategy and Future Made in Australia.
By profiling members like BiomeBank, we help connect Australia's life sciences ecosystem — including innovators, investors, policymakers, and partners — and elevate out member voices to national and international audiences.
Since launching Spotlight, we have seen strong engagement. Our previous feature on medtech innovator Navbit attracted more than 5,000 views across our channels — a clear signal that there is strong interest in homegrown stories of innovation and commercialisation. We look forward to seeing BiomeBank's story shared just as widely.
We look forward to sharing BiomeBank's story as part of that ongoing conversation.
If you missed the first episode of Spotlight, you can watch it here.
Together, we are building a stronger, more connected Australian life sciences sector — one story at a time.
